AETHLON MEDICAL INC (AEMD): Company Overview NOVEMBER 2026

AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Company Overview NOVEMBER 2026 1 2 Disclaimer This presentation (together with any information communicated orally in connection herewith, this "Presentation") is being pr ovi ded by North Immunology, Inc. ("North" or the "Company") on a confidential basis solely for

Event
Role
acquirer
ReportedM&AOffering · $180M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 16, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$AEMD
Neutral
medium confidence
Mentioned
$AEMD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AEMDNeutralMed
01

Why it matters

This is an event-driven catalyst tied to transaction execution and financing conditions. However, the excerpt is largely boilerplate and forward-looking language, with no deal terms, pricing, or definitive timeline beyond references to filing and effectiveness steps.

02

Market read

Traders should monitor the next SEC filings (S-4, proxy/prospectus) and any updates on financing sufficiency and closing conditions, as these can drive deal-risk repricing.

03

What to watch

Key trading signals will likely come later from the S-4 effectiveness, stockholder approvals, minimum financing details, and any exchange listing approval, none of which are specified here.

Relevance 4/10Novelty 4/10Timing: today’s SEC filing references an upcoming S-4 and proxy/prospectus process for the proposed transaction.

Background

The 8-K (Item 7.01) furnishes a “Company Overview November 2026” presentation describing a proposed private placement and a proposed business combination where a successor entity to North would become a wholly owned subsidiary of AEMD.

Company-level read

Ticker impact

$AEMDNeutralMedium confidence
Context

AEMD files an 8-K Item 7.01 Regulation FD disclosure tied to a proposed business combination with North Immunology and a concurrent private placement.

Expected impact

Likely mixed-to-negative near term if investors focus on deal execution and financing/closing-condition risk, but could stabilize if the market views the transaction as adequately funded.

Evidence & confidence

The text is a Regulation FD disclosure describing a proposed transaction and private placement mechanics, without providing deal economics or definitive closing certainty.

Market effects

Biotech M&A and financing expectations may shift modestly, but the disclosure lacks trial or regulatory catalysts.

No clear regional market linkage beyond US-listed biotech deal activity.

Limited, as the disclosure is US SEC process related to a specific issuer transaction.

Counterpoint

Investors may treat this as mostly procedural disclosure, discounting it until the S-4/proxy/prospectus provides concrete terms and financing amounts.

Key entities

  • Aethlon Medical, Inc.

    Nasdaq-listed company (AEMD) that is party to the proposed business combination and private placement described in the Regulation FD disclosure.

  • North Immunology, Inc.

    Company referenced as the counterparty in the proposed transaction; described as providing the presentation on a confidential basis.

Related articles

$AEMDMed

Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update

AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update SAN DIEGO, November 12, 2026 -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results for

$AEMDMed

Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update

Aethlon Medical (AEMD) reported Q2 2027 results, including $6.5M in cash, $2.7M in operating expenses, and progress in a Phase 1 oncology study. The company announced a merger with North Immunology, with shareholders to receive contingent value rights. The merger may lead to workforce reductions and wind-down of legacy activities. The company remains operational and continues to evaluate resources.

$LSTAHighAI 9/10

Lisata and Aethlon close reverse merger deals

Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock deal with a $225M private placement, gaining access to Marea's cardioendocrine pipeline. Aethlon Medical merged with North Immunology in an all-stock deal with a $180M private placement, focusing on NOR-101 for atopic dermatitis. Both deals aim to advance pipelines and create value for shareholders.

$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo